Stephen Roberts Walsh, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
AIDS Vaccines | 16 | 2023 | 938 | 2.460 |
Why?
|
Vaccinia virus | 8 | 2023 | 349 | 1.330 |
Why?
|
Smallpox Vaccine | 5 | 2013 | 80 | 1.310 |
Why?
|
HIV-1 | 19 | 2023 | 6939 | 1.290 |
Why?
|
HIV Antibodies | 14 | 2023 | 1322 | 1.140 |
Why?
|
Antibodies, Neutralizing | 16 | 2023 | 1978 | 0.800 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 5 | 2021 | 370 | 0.740 |
Why?
|
Immunization, Passive | 1 | 2021 | 623 | 0.660 |
Why?
|
HIV Infections | 18 | 2023 | 16718 | 0.630 |
Why?
|
Orthopoxvirus | 1 | 2012 | 11 | 0.440 |
Why?
|
Vaccinia | 1 | 2013 | 76 | 0.430 |
Why?
|
Poxviridae Infections | 1 | 2011 | 12 | 0.410 |
Why?
|
Adenoviruses, Human | 4 | 2014 | 257 | 0.400 |
Why?
|
Vaccines, Combined | 4 | 2023 | 69 | 0.380 |
Why?
|
Vaccination | 7 | 2023 | 3278 | 0.380 |
Why?
|
Meningococcal Vaccines | 2 | 2023 | 95 | 0.370 |
Why?
|
Genetic Vectors | 7 | 2023 | 3420 | 0.370 |
Why?
|
Epitopes, T-Lymphocyte | 2 | 2015 | 880 | 0.360 |
Why?
|
Double-Blind Method | 17 | 2023 | 12026 | 0.340 |
Why?
|
Antibodies, Viral | 9 | 2022 | 3176 | 0.310 |
Why?
|
Antibodies, Monoclonal | 4 | 2022 | 9274 | 0.280 |
Why?
|
Vaccines, Synthetic | 6 | 2022 | 634 | 0.250 |
Why?
|
Immunization Schedule | 4 | 2020 | 221 | 0.250 |
Why?
|
Vaccines | 2 | 2023 | 822 | 0.240 |
Why?
|
Vaccines, DNA | 2 | 2023 | 305 | 0.240 |
Why?
|
Clindamycin | 1 | 2004 | 139 | 0.240 |
Why?
|
Uremia | 1 | 2005 | 201 | 0.240 |
Why?
|
Fasciitis, Necrotizing | 1 | 2004 | 79 | 0.230 |
Why?
|
Immunization, Secondary | 2 | 2022 | 340 | 0.230 |
Why?
|
Viral Vaccines | 2 | 2020 | 636 | 0.220 |
Why?
|
Immunity, Cellular | 5 | 2023 | 1607 | 0.220 |
Why?
|
Meningococcal Infections | 1 | 2023 | 77 | 0.220 |
Why?
|
Herpesviridae | 1 | 2003 | 109 | 0.210 |
Why?
|
Streptococcus pyogenes | 1 | 2004 | 289 | 0.210 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2018 | 5442 | 0.210 |
Why?
|
Gene Products, env | 2 | 2012 | 263 | 0.200 |
Why?
|
Adjuvants, Immunologic | 3 | 2022 | 1000 | 0.200 |
Why?
|
Lymphopenia | 1 | 2023 | 285 | 0.190 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2021 | 323 | 0.180 |
Why?
|
Young Adult | 19 | 2023 | 56430 | 0.180 |
Why?
|
Chloroquine | 1 | 2021 | 280 | 0.180 |
Why?
|
Vaccines, Inactivated | 1 | 2020 | 184 | 0.170 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2012 | 4479 | 0.170 |
Why?
|
Immunoglobulin Fab Fragments | 1 | 2021 | 482 | 0.170 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 2021 | 279 | 0.170 |
Why?
|
Genome, Viral | 1 | 2003 | 667 | 0.170 |
Why?
|
HIV Seropositivity | 2 | 2022 | 971 | 0.170 |
Why?
|
Macaca mulatta | 2 | 2020 | 2375 | 0.170 |
Why?
|
HIV Antigens | 2 | 2020 | 347 | 0.170 |
Why?
|
Neurophysiology | 1 | 2020 | 142 | 0.170 |
Why?
|
Primates | 1 | 2021 | 545 | 0.160 |
Why?
|
Antiviral Agents | 4 | 2022 | 2987 | 0.160 |
Why?
|
Immunocompromised Host | 2 | 2014 | 847 | 0.160 |
Why?
|
T-Lymphocytes | 1 | 2015 | 10180 | 0.150 |
Why?
|
Receptors, Virus | 1 | 2021 | 648 | 0.150 |
Why?
|
Dose-Response Relationship, Immunologic | 3 | 2013 | 370 | 0.150 |
Why?
|
Hydroxychloroquine | 1 | 2021 | 412 | 0.150 |
Why?
|
Drug Therapy, Combination | 3 | 2021 | 6489 | 0.150 |
Why?
|
Drug Carriers | 3 | 2018 | 693 | 0.150 |
Why?
|
Drug Resistance, Bacterial | 1 | 2004 | 1035 | 0.140 |
Why?
|
Vaccines, Attenuated | 3 | 2013 | 342 | 0.140 |
Why?
|
Skin Diseases | 1 | 2005 | 1065 | 0.140 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 5 | 2016 | 3870 | 0.140 |
Why?
|
HIV | 1 | 2003 | 1604 | 0.130 |
Why?
|
Epidemics | 1 | 2021 | 523 | 0.130 |
Why?
|
Adult | 27 | 2023 | 214055 | 0.130 |
Why?
|
Immunologic Memory | 1 | 2021 | 1348 | 0.130 |
Why?
|
Humans | 48 | 2023 | 744343 | 0.130 |
Why?
|
Adenoviridae | 2 | 2016 | 1099 | 0.120 |
Why?
|
Models, Animal | 1 | 2021 | 2171 | 0.120 |
Why?
|
Gene Expression | 2 | 2020 | 7799 | 0.120 |
Why?
|
Paramyxoviridae Infections | 1 | 2014 | 55 | 0.120 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2021 | 4386 | 0.120 |
Why?
|
Fowlpox virus | 1 | 2012 | 20 | 0.110 |
Why?
|
Injections, Intramuscular | 4 | 2020 | 552 | 0.110 |
Why?
|
Exercise Therapy | 1 | 2020 | 906 | 0.110 |
Why?
|
Female | 30 | 2023 | 380194 | 0.110 |
Why?
|
Kidney Failure, Chronic | 1 | 2005 | 2538 | 0.110 |
Why?
|
Forecasting | 1 | 2021 | 2951 | 0.100 |
Why?
|
Dendritic Cells | 1 | 2003 | 2725 | 0.100 |
Why?
|
Male | 27 | 2023 | 350118 | 0.100 |
Why?
|
Low Back Pain | 1 | 2020 | 956 | 0.100 |
Why?
|
Immunity, Mucosal | 1 | 2014 | 490 | 0.100 |
Why?
|
Middle Aged | 20 | 2023 | 213383 | 0.100 |
Why?
|
Capsid Proteins | 1 | 2014 | 479 | 0.090 |
Why?
|
Adolescent | 10 | 2023 | 85781 | 0.090 |
Why?
|
Placebos | 3 | 2021 | 1676 | 0.090 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2021 | 2026 | 0.090 |
Why?
|
Cyclooxygenase 2 | 1 | 2011 | 611 | 0.080 |
Why?
|
Antigens, Viral | 1 | 2013 | 1035 | 0.080 |
Why?
|
Recombinant Proteins | 2 | 2022 | 6622 | 0.080 |
Why?
|
Antibody Formation | 3 | 2020 | 1402 | 0.070 |
Why?
|
Recombinant Fusion Proteins | 1 | 2014 | 3772 | 0.060 |
Why?
|
Pneumonia, Staphylococcal | 1 | 2005 | 43 | 0.060 |
Why?
|
Chronic Disease | 1 | 2020 | 9146 | 0.060 |
Why?
|
Meningitis, Viral | 1 | 2004 | 50 | 0.060 |
Why?
|
Meningitis, Aseptic | 1 | 2004 | 58 | 0.060 |
Why?
|
Intestinal Mucosa | 2 | 2014 | 3036 | 0.060 |
Why?
|
Cancer Vaccines | 1 | 2011 | 1023 | 0.060 |
Why?
|
Treatment Outcome | 7 | 2020 | 63114 | 0.060 |
Why?
|
Exercise | 1 | 2020 | 5615 | 0.060 |
Why?
|
Animals | 7 | 2023 | 168757 | 0.060 |
Why?
|
Herpesvirus 2, Human | 1 | 2004 | 189 | 0.050 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2009 | 1366 | 0.050 |
Why?
|
Immunity, Humoral | 2 | 2018 | 598 | 0.050 |
Why?
|
Pregnancy | 2 | 2021 | 29144 | 0.050 |
Why?
|
Neoplasms | 1 | 2011 | 21683 | 0.050 |
Why?
|
Virus Replication | 2 | 2003 | 2534 | 0.050 |
Why?
|
Leukocytes, Mononuclear | 3 | 2014 | 1836 | 0.050 |
Why?
|
Vaccines, Conjugate | 1 | 2023 | 333 | 0.050 |
Why?
|
Graft vs Host Disease | 1 | 2014 | 2957 | 0.050 |
Why?
|
Herpes Simplex | 1 | 2004 | 470 | 0.050 |
Why?
|
Immunosuppressive Agents | 1 | 2014 | 4149 | 0.050 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2023 | 629 | 0.050 |
Why?
|
Interferon-gamma | 1 | 2009 | 3206 | 0.050 |
Why?
|
Diabetic Foot | 1 | 2004 | 355 | 0.050 |
Why?
|
Injections, Intradermal | 2 | 2010 | 117 | 0.050 |
Why?
|
Fatal Outcome | 1 | 2005 | 1850 | 0.050 |
Why?
|
Cell Line | 2 | 2013 | 15997 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2023 | 841 | 0.040 |
Why?
|
Lactation | 1 | 2022 | 412 | 0.040 |
Why?
|
Viremia | 1 | 2022 | 736 | 0.040 |
Why?
|
Peru | 1 | 2021 | 881 | 0.040 |
Why?
|
Microbial Sensitivity Tests | 1 | 2004 | 1877 | 0.040 |
Why?
|
Poland Syndrome | 1 | 1997 | 14 | 0.040 |
Why?
|
Dextrocardia | 1 | 1997 | 37 | 0.040 |
Why?
|
Vaccines, Subunit | 1 | 2018 | 168 | 0.040 |
Why?
|
Sepsis | 1 | 2011 | 2593 | 0.040 |
Why?
|
Antibodies, Bacterial | 1 | 2023 | 1470 | 0.040 |
Why?
|
Orthoreovirus | 1 | 1996 | 23 | 0.040 |
Why?
|
HIV Envelope Protein gp120 | 1 | 2021 | 952 | 0.040 |
Why?
|
DNA | 2 | 2021 | 7301 | 0.040 |
Why?
|
Africa, Eastern | 1 | 2016 | 71 | 0.030 |
Why?
|
Giant Cells | 1 | 1996 | 187 | 0.030 |
Why?
|
Pneumonia, Viral | 1 | 2014 | 3240 | 0.030 |
Why?
|
Immunity | 1 | 2021 | 1012 | 0.030 |
Why?
|
Placebo Effect | 1 | 2019 | 502 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 4751 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2021 | 15540 | 0.030 |
Why?
|
Epitopes | 1 | 2021 | 2571 | 0.030 |
Why?
|
Plasmids | 1 | 2020 | 2307 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2022 | 9959 | 0.030 |
Why?
|
International Cooperation | 1 | 2021 | 1420 | 0.030 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2014 | 130 | 0.030 |
Why?
|
Consensus | 1 | 2023 | 2959 | 0.030 |
Why?
|
Wound Healing | 1 | 2004 | 2785 | 0.030 |
Why?
|
Pandemics | 2 | 2023 | 8388 | 0.030 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2021 | 1873 | 0.030 |
Why?
|
Retrospective Studies | 1 | 2021 | 77449 | 0.030 |
Why?
|
Viral Load | 1 | 2021 | 3299 | 0.030 |
Why?
|
Patient Participation | 1 | 2021 | 1457 | 0.030 |
Why?
|
Skin | 1 | 2005 | 4364 | 0.020 |
Why?
|
Caco-2 Cells | 1 | 2011 | 387 | 0.020 |
Why?
|
South Africa | 1 | 2016 | 1731 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2018 | 39050 | 0.020 |
Why?
|
Virus Shedding | 1 | 2010 | 108 | 0.020 |
Why?
|
Cell Membrane Permeability | 1 | 2011 | 590 | 0.020 |
Why?
|
Peritonitis | 1 | 2011 | 365 | 0.020 |
Why?
|
Ileum | 1 | 2011 | 565 | 0.020 |
Why?
|
Prednisone | 1 | 2014 | 1574 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2021 | 5097 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2021 | 8642 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2010 | 666 | 0.020 |
Why?
|
United States | 3 | 2023 | 69872 | 0.020 |
Why?
|
Odds Ratio | 1 | 2021 | 9849 | 0.020 |
Why?
|
Sex Factors | 1 | 2021 | 10397 | 0.020 |
Why?
|
Immunotherapy | 1 | 2003 | 4445 | 0.020 |
Why?
|
Aged | 4 | 2022 | 163280 | 0.020 |
Why?
|
Comorbidity | 1 | 2021 | 10388 | 0.020 |
Why?
|
Sirolimus | 1 | 2014 | 1564 | 0.020 |
Why?
|
Colon | 1 | 2014 | 1772 | 0.020 |
Why?
|
Respiratory Insufficiency | 1 | 2014 | 1199 | 0.020 |
Why?
|
Hypertension | 1 | 2005 | 8480 | 0.020 |
Why?
|
Age Factors | 1 | 2021 | 18370 | 0.020 |
Why?
|
Bacteremia | 1 | 2011 | 962 | 0.020 |
Why?
|
Time Factors | 2 | 2020 | 40075 | 0.010 |
Why?
|
Risk Assessment | 1 | 2004 | 23338 | 0.010 |
Why?
|
Respiration, Artificial | 1 | 2014 | 2569 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2011 | 6386 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2018 | 13989 | 0.010 |
Why?
|
Cytokines | 1 | 2014 | 7322 | 0.010 |
Why?
|
Cohort Studies | 1 | 2021 | 40561 | 0.010 |
Why?
|
Prospective Studies | 1 | 2023 | 53288 | 0.010 |
Why?
|
DNA, Viral | 1 | 2004 | 2225 | 0.010 |
Why?
|
Brefeldin A | 1 | 1996 | 72 | 0.010 |
Why?
|
Cytopathogenic Effect, Viral | 1 | 1996 | 156 | 0.010 |
Why?
|
Tunicamycin | 1 | 1996 | 112 | 0.010 |
Why?
|
Protein Synthesis Inhibitors | 1 | 1996 | 192 | 0.010 |
Why?
|
Cyclopentanes | 1 | 1996 | 91 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2021 | 57776 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2011 | 14557 | 0.010 |
Why?
|
Deoxyglucose | 1 | 1996 | 337 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2011 | 21827 | 0.010 |
Why?
|
Child | 1 | 2021 | 77709 | 0.010 |
Why?
|
Recurrence | 1 | 2004 | 8340 | 0.010 |
Why?
|
Biological Transport | 1 | 1996 | 2118 | 0.010 |
Why?
|
Viral Proteins | 1 | 1996 | 1900 | 0.010 |
Why?
|
Mice | 2 | 2011 | 81183 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1996 | 6314 | 0.010 |
Why?
|
Infant, Newborn | 1 | 1997 | 25625 | 0.000 |
Why?
|